Direct Oral Anticoagulants in Patients With Active Cancer: A Systematic Review and Meta-Analysis.

ABSTRACT:

Background

Many patients with cancer have a hypercoagulable state and an increased risk of developing venous thromboembolism (VTE), arterial occlusion, and pulmonary emboli. Patients with cancer may also have an increased risk of bleeding with anticoagulant treatment. Recent trials have reported that direct oral anticoagulants (DOACs) are noninferior to the low-molecular-weight heparin, dalteparin, in preventing VTE, but have a higher bleeding rate.

Objectives

This study compared the efficacy and risks of DOACs versus dalteparin in patients with cancer-related VTEs across all randomized controlled trials (RCTs).

Methods

This study performed a systematic analysis of RCTs published in PubMed, SCOPUS, and Google Scholar from September 1, 2007 through March 31, 2020 that

SUBMITTER: Sabatino J 

PROVIDER: S-EPMC8352218 | biostudies-literature | 2020 Sep

REPOSITORIES: biostudies-literature